ABCL
Price
$2.92
Change
+$0.07 (+2.46%)
Updated
Dec 23, 03:52 PM (EDT)
64 days until earnings call
AKBA
Price
$1.85
Change
+$0.02 (+1.09%)
Updated
Dec 23, 03:53 PM (EDT)
79 days until earnings call
Ad is loading...

ABCL vs AKBA

Header iconABCL vs AKBA Comparison
Open Charts ABCL vs AKBABanner chart's image
AbCellera Biologics
Price$2.92
Change+$0.07 (+2.46%)
Volume$7.66K
CapitalizationN/A
Akebia Therapeutics
Price$1.85
Change+$0.02 (+1.09%)
Volume$4.5K
CapitalizationN/A
ABCL vs AKBA Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. AKBA commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and AKBA is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (ABCL: $2.85 vs. AKBA: $1.83)
Brand notoriety: ABCL and AKBA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 83% vs. AKBA: 253%
Market capitalization -- ABCL: $838.84M vs. AKBA: $400.36M
ABCL [@Biotechnology] is valued at $838.84M. AKBA’s [@Biotechnology] market capitalization is $400.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileAKBA’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • AKBA’s FA Score: 0 green, 5 red.
According to our system of comparison, ABCL is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 5 TA indicator(s) are bullish while AKBA’s TA Score has 5 bullish TA indicator(s).

  • ABCL’s TA Score: 5 bullish, 3 bearish.
  • AKBA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than AKBA.

Price Growth

ABCL (@Biotechnology) experienced а +1.42% price change this week, while AKBA (@Biotechnology) price change was -1.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.15%. For the same industry, the average monthly price growth was -2.89%, and the average quarterly price growth was +3.31%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 25, 2025.

AKBA is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-2.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($839M) has a higher market cap than AKBA($400M). AKBA YTD gains are higher at: 47.581 vs. ABCL (-50.088). AKBA has higher annual earnings (EBITDA): 4.3M vs. ABCL (-202.4M). ABCL has more cash in the bank: 643M vs. AKBA (34M). AKBA has less debt than ABCL: AKBA (48.6M) vs ABCL (71.4M). AKBA has higher revenues than ABCL: AKBA (170M) vs ABCL (33M).
ABCLAKBAABCL / AKBA
Capitalization839M400M210%
EBITDA-202.4M4.3M-4,710%
Gain YTD-50.08847.581-105%
P/E RatioN/AN/A-
Revenue33M170M19%
Total Cash643M34M1,891%
Total Debt71.4M48.6M147%
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLAKBA
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
75%
Momentum
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 12 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
85%
Aroon
ODDS (%)
Bullish Trend 5 days ago
66%
Bullish Trend 4 days ago
88%
View a ticker or compare two or three
Ad is loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VADAX71.931.00
+1.41%
Invesco Equally-Wtd S&P 500 A
RYROX45.120.42
+0.94%
Rydex Russell 2000 C
RMATX10.590.06
+0.57%
Russell Inv Multi-Asset Growth Strat M
WICVX10.060.01
+0.10%
Wasatch Small Cap Value Institutional
TVSVX18.000.01
+0.06%
Third Avenue Small Cap Value Investor

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with VCYT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+5.17%
VCYT - ABCL
56%
Loosely correlated
+4.66%
BEAM - ABCL
55%
Loosely correlated
+8.04%
PRME - ABCL
55%
Loosely correlated
+3.94%
DNA - ABCL
53%
Loosely correlated
+15.33%
AURA - ABCL
53%
Loosely correlated
+1.11%
More

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+2.23%
ABOS - AKBA
42%
Loosely correlated
+2.78%
KOD - AKBA
41%
Loosely correlated
-0.35%
ABCL - AKBA
41%
Loosely correlated
+5.17%
BEAM - AKBA
40%
Loosely correlated
+8.04%
INZY - AKBA
39%
Loosely correlated
+6.41%
More